Litcius/Paper detail

Zandelisib with continuous or intermittent dosing as monotherapy or in combination with rituximab in patients with relapsed or refractory B-cell malignancy: a multicentre, first-in-patient, dose-escalation and dose-expansion, phase 1b trial

John M. Pagel, Jacob D. Soumerai, Nishitha Reddy, Deepa Jagadeesh, Anastasios Stathis, Adam Asch, Huda Salman, Vaishalee P. Kenkre, Alexia Iasonos, Judith Llorin-Sangalang, Joanne Li, Andrew D. Zelenetz

2022The Lancet Oncology26 citationsDOIOpen Access PDF

Topics & Concepts

MedicineDosingTolerabilityAdverse effectRefractory (planetary science)RituximabInternal medicineFollicular lymphomaNauseaMaximum tolerated doseOncologyGastroenterologyPharmacologyLymphomaPhysicsAstrobiologyPI3K/AKT/mTOR signaling in cancerChronic Lymphocytic Leukemia ResearchUbiquitin and proteasome pathways
Zandelisib with continuous or intermittent dosing as monotherapy or in combination with rituximab in patients with relapsed or refractory B-cell malignancy: a multicentre, first-in-patient, dose-escalation and dose-expansion, phase 1b trial | Litcius